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Introduction.  Newborn screening (NBS) programs are implemented as government sponsored 
public health initiatives. They aim to identify infants affected by inborn disorders that can result 
in mortality or lifelong disability in the absence of immediate treatment. Once at-risk infants are 
detected, parents are then re-contacted to have their children undergo confirmatory diagnostic 
testing. Most industrialised countries screen for PKU and congenital hypothyroidism. There are 
also programs that target specific geographic areas, where populations are at higher risk for 
disorders such as thalassaemia or sickle cell disease. Some of these targeted programs are 
currently being integrated into universal screening programs where the population is comprised 
of high-risk groups for certain diseases1.  
 
A few major trends are influencing the development of NBS programs throughout the world. At 
the outset, technological advances, such as the introduction of tandem mass spectrometry 
(MS/MS), allow bloodspot testing to identify a wider range of conditions. Indeed, at least 30 
disorders, some of which are not treatable, can now be detected in a single process by using the 
same dried blood specimen collected in the course of routine newborn screening programmes.2 
The introduction of new technologies for the genetic testing of newborns, such as tandem mass 
spectrometry, and DNA microarray technology (DNA chip) has prompted ethical concerns about 
extending the range of disorders to be detected towards those which include quality of life issues 
and psychological benefits to the child and or parents, as well as the need for consent and to 
inform parents about these technological advances. 
 
Blood spots can be used repeatedly and stored for a long time. In addition, storage practices of 
newborn bloodspots vary internationally. Some countries like Denmark store cards indefinitely, 
while others destroy their cards after completing the necessary quality check. The variability of 
storage practices raises concerns around newborn screening programs. For instance, what should 
parents be told about storage and about the subsequent use of dried blood spots? Whilst generally 
most routine newborn screening programs have not required parental consent for storage and 
future use, ethical concerns about patient privacy, confidentiality and autonomy are influencing a 
re-examination of this policy.  
 
Existing policies diverge on the manner in which consent is solicited and the way information is 
presented to parents in the case of disorders amenable to treatment; of disorders for which no 
treatment is available; and of storage and of future use of stored samples. The issue of consent, 
refusal or choice and the practicality of written consent will vary according to circumstances.  
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This GenEdit critically examines how existing guidelines and policy statements have addressed: 
(I) consent to screening for treatable diseases, (II) consent for untreatable diseases/and a wider 
range of disorders, (III) consent to storage, and (IV) consent to future uses of stored samples. 
Finally we conclude with a few recommendations to help address the issues of informed 
decision-making.  
 
 
I. Explicit or presumed consent to newborn screening for treatable disorders  
 
Classical newborn screening for routine/treatable disorders has been and is being carried out, in 
most parts of the world without explicit parental consent.(See TABLE 1) In newborn screening 
programs, consent is presumed and justified on the basis that when a disease is treatable, a 
newborn has a right to be screened and to be treated.3  
 
What constitutes a treatable disorder? In general, newborn screening is recommended for a 
disorder where: 1) there is considered to be a direct benefit to the newborn from early diagnosis; 
2) the benefit is reasonably balanced against financial and other costs; 3) there is a reliable test 
suitable for neonatal screening; and 4) there is a satisfactory system in operation to deal with 
diagnostic testing, counselling, treatment and follow-up of identified babies.4 This is best 
exemplified by a disorder like PKU, where early detection by screening and treatment has been 
very effective in preventing neurological abnormalities. 
 
Most newborn screening programs are part of mandated paediatric norms and are considered part 
of routine care, thus eliminating the requirement for a separate written consent. The rationale for 
this practice stems from the belief that the minimal risk of adverse medical effects associated 
with the collection of a few drops of blood versus the significant medical consequences of a 
missed case due to parental refusal can justify the absence of formal informed consent. Also 
consent is presumed because it is defined in term of the best interest of the child and of society. 
Indeed, the New York Task Force states that “that the autonomy of the parent to make health care 
decisions for their minor children must give way to the state’s role in protecting children from 
harm”5. In 1998, the World Health Organisation (WHO) declared that newborn screening should 
be mandatory and free of charge if early diagnosis and treatment will benefit the newborn.6 
Although the WHO position does not outright state that parents should not be able to refuse 
interventions that are beneficial to their children, some have interpreted it to mean exactly that.7
 
Those who support a choice approach for screening argue that obtaining consent will not 
compromise uptake for screening, that parents have a right not to know, and maintain the general 
principle of consent for any intervention.8  
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Though most newborn screening programs screen for treatable disorders without explicit consent, 
there is general agreement amongst guidelines that parents should be adequately informed about 
newborn screening. The International Society for Neonatal Screening (ISNS), for instance, 
underlines the importance of informing parents and of public education about newborn screening 
programmes.9 It advocates that the public be kept well informed about screening programmes 
and that as far as possible, written information be provided to parents before screening. The 
Human Genetics Society of Australasia adds that written information and the opportunity for 
discussion must be provided to parents before testing and that health professionals should be 
provided with comprehensive guidelines describing all aspects of the screening program 
including correct sample collection procedure.10
 
Both the ISNS and the HGSA make no specific mention of written consent, they do however 
underline the need for public education and mechanisms that appropriately address a parent’s 
option to decline testing and that they be kept informed of the possible consequences should they 
chose to refuse NBS.11  
 
The American states of Wyoming and Maryland have NBS programs, which utilize explicit 
written consent12, notwithstanding the Association of Public Health Laboratories’ (APHL) 
statement to the effect that explicit parental consent is not necessary for mandated public health 
newborn screening13. In contrast, New York, which used to seek informed consent to test 
newborn blood specimens for HIV, now has added HIV to the mandatory program through 
legislative and regulatory amendments.14  
 
The question arises whether the “mandatory offering” interpretation is inconsistent with the 
Human Genetics Society of Australasia (HGSA) position stating that participation in a newborn 
screening program should not be mandatory15, as well as the Institute of Medicine’s 
recommendation promoting voluntariness of newborn screening programs16. Indeed mandatory 
offering provides for an opt-out but presumes consent. 
 
The UK Newborn Screening Programme Centre is examining a different solution to written 
consent for screening. While recognising the importance of accurate information as essential to 
enable parental decision to screening, the recently proposed standards and policies reject the 
written consent model, opting instead for an ‘informed choice’ approach with recording of 
acceptance or decline to NBS in the mother’s maternity record.17  
 
In short, the UK18, Canada19, and the USA (See TABLE 2) have opted for the presumed consent 
model where parents are invited to sign admission papers and consent to NBS as part of routine 
paediatric procedures when they arrive at the hospital at the time of delivery.  
 
When screening for medical conditions which when detected in the newborn period can be 
treated immediately, most guidelines concur that presumed consent is appropriate20. However, 
the policies indicate that professionals have a responsibility to inform and provide ongoing 
support and that explicit written consent21 and/or more detailed information22 is a goal to strive 
for. 
 
II. Explicit or presumed consent to screening for a wider range of treatable and non-
treatable disorders  
 
With the introduction of tandem mass spectrometry (MS/MS) for population based newborn 
screening, healthcare providers are now able to detect an increased number of disorders in a 
single process by using the same dried blood spot specimen collected through routine newborn 
screening. Unfortunately, effective treatments are not available for all diseases that can be 
identified by MS/MS.  
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NBS for new disorders, raises novel issues about consent. First a dilemma has emerged on the 
definition of “benefit”. Benefit has meant direct medical benefit, where early diagnosis and 
medical intervention improves outcomes23. Others have suggested that benefit is for the family as 
well as for the baby.24 For example, parental knowledge has been alleged to lessen self-blame, 
prevent weeks or months of searching for a diagnosis and has allowed parents to take advantage 
of new and rapidly evolving treatment.25 Early diagnosis, at birth, has also been suggested to 
avoid trauma and expense to the family, and allow options for family planning to be considered 
before other affected siblings are born.26  Similarly, it has been argued that knowing an infant is a 
carrier, has the potential for stigmatization and alters self-perception27.  
 
Given the absence of direct medical benefit and the deviation from the classical criteria of 
newborn screening, most guidelines concur that NBS programs, which elect to include new 
disorders, such as cystic fibrosis, that are treatable but where immediacy of detection is not an 
issue or conditions that are untreatable, should require explicit parental consent in the spirit of 
informed participation in medical procedures of limited or unproven benefit. This having been 
said, seeking explicit consent for the screening of untreatable disorders can have undesired 
outcomes. Indeed, preliminary studies from a pilot project in Scotland appear to indicate, that 
seeking written consent for the screening of both treatable and untreatable (Cystic Fibrosis in the 
case of Scotland) diseases in a single process leads to more parents refusing screening 
altogether.28  Thus it seems logical that consent be presumed for screening of treatable disorders 
and explicit in the case of untreatable ones. 
 
III. Explicit or presumed consent to store newborn bloodspots 
 
Once the newborn screening programme is completed, residual dried blood spots (DBS) are 
either discarded or stored in public health laboratories. Storing DBS for up to one year is 
indispensable for repeat-testing, normal laboratory audit and quality assurance purposes (QA). 
However, because bloodspots constitute valuable DNA specimens, they may also be of benefit 
for familial, forensic and research purposes. Indeed, stored samples could be used to conduct pre-
symptomatic and susceptibility genetic testing or paternity testing, thus revealing information 
about children, which is not necessarily in their best interest and usually contrary to most genetic 
predictive testing guidelines.29  The existence of these collections raises ethical concerns about 
access by insurers, employers, families, law enforcement agencies and others. There is currently 
apprehension regarding the possible misuse of stored samples as well as intrusion into privacy.  
 
Whatever the objectives for retaining newborn blood spots, it is recommended that public health 
newborn screening programs thoroughly evaluate and define the rationale for storage and 
analysis beyond that necessary for confirmatory testing and quality control30.  
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A central ethical question regarding storage of newborn bloodspots is whether parental consent is 
needed for storage beyond the time needed for quality assurance and for subsequent research use 
of the samples. Based on the principles of autonomy and respect for privacy, consent is usually 
required when human biological materials are collected and stored for future use.  In its 2003 
International Declaration on Human Genetic Data31, UNESCO states that prior, free, informed 
and express consent should be obtained for the collection of human genetic data, human 
proteomic data or biological samples, whether through invasive or non-invasive procedures, and 
for their subsequent processing, use and storage unless prescribed by domestic law consistent 
with the international law of human rights. It is not clear whether this declaration can be applied 
to the collection of newborn dried bloodspots because there is no mention of samples collected 
by newborn screening programs for initial diagnosis, not essentially related to the study of 
genetic characteristics. (See TABLE 3) 
 
While most policy statements that address storage of newborn dried blood spots strongly agree 
that parents and the public in general should be informed about storage policies and practices32, 
most do not require written consent for storage. The American Academy of Pediatrics Newborn 
Screening Taskforce has recommended developing model consent forms and informational 
materials for parental permission for retention of DBS.33 The Association française pour le 
dépistage et la prevention des handicaps de l’enfant (AFDPHE), for its part, has also 
recommended that written consent for storage be obtained when bloodspots are planned to be 
used for purposes other than those for which they were initially obtained.34    
 
Another solution is the Danish approach with regard to consent to storage, where parents are 
informed and given the opportunity to opt-out from having their child’s bloodspot stored at the 
time of screening.35 In other words, informed refusal is generally favoured over informed 
consent.36
 
There are currently no policies governing the storage and use of residual blood samples in 
Canada, and a recently pilot survey demonstrates that parents are generally not informed nor are 
they asked to consent to storage.37
 
In brief, when samples are retained beyond the one-year period required for quality assurance, 
informing parents at the time of collection about length, purposes and methods of storage as well 
the confidentiality of stored samples is considered to be good practice. 
 
IV – Explicit or presumed consent to use dried bloodspot cards 
 
Using residual bloodspots for purposes other than those for which they were obtained can 
become more or less problematic depending on the use. The research use of bloodspots raises 
concern about confidentiality and about group harms, especially concerns about stigmatization 
and discrimination against those who test positive for example if the research involves genes 
associated with behaviour. Employers, health insurers, schools, or other institutions might want 
to access individual health records and dried blood samples. Seeing as a newborn’s bloodspot is a 
valuable source of genetic information, it has been recommended that screening programs ensure 
that DBS and associated information are stored in a secure manner to prevent unauthorised access 
and secondary use of identified or identifiable samples.38 While using anonymized DBS for 
epidemiological or public health research does not threaten patient privacy, research with coded 
samples create the possibility of re-contacting patients for follow-up studies, and so ethical 
challenges arise.  
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Since the primary purpose of newborn bloodspot collection is for diagnosis and confirmatory 
testing, most guidelines maintain that further uses of stored samples, for purposes other than 
screening program audit/epidemiological use, require either written permission from the 
individual, the parents or guardian, a legally binding directive, or appropriate ethics committee 
approval for research studies.39 There is also general agreement that anonymized samples are 
important for health surveillance studies. Consequently, they should be made available for 
research without parental consent and because they represent less of a threat to patient privacy 
than coded or identified samples.40  
 
The prospect of storing newborn bloodspots raises questions of when and how to inform parents. 
Some guidelines have stated that information about additional uses of newborn samples should 
be conveyed to parents and that an up-front mechanism of informed consent, at the time of heel 
prick collection, would be a logical way of initiating the process.41 Indeed, this process seems 
acceptable if a research project is foreseen before sample collection. But what about when 
consent to storage and future research use is required before the actual research protocol has been 
elaborated? The WHO42 as well as the Danish Neonatal Screening Programme43 have 
recommended blanket consent for all residual bloodspot use. Whilst constituting an efficient and 
economical method, this approach can be criticized based on the fact that it does not allow 
parents to fully understand the exact future purposes of stored samples and prevents them from 
providing a truly informed consent. It has been suggested that specific consent, through re-
contact, should be obtained for each research study that requires coded or identified samples.44 
(See TABLE 3) 
 
Conclusion and Recommendations 
 
Policies in favour of mandatory screening (with presumed consent) for treatable disorders, while 
appearing to override parental consent, are implemented in the child’s best interest. The majority 
of policies and professional groups agree that the benefits of NBS are so great for the newborn 
and in the child’s best interest that the screening should be universal and mandatory. While 
mandatory offering of newborn screening is a public health responsibility as it is the child’s best 
interest to be screened and found, it is an area where the rights of the child and the right of the 
parents may appear to be in conflict. For example this conflict is reflected more and more in 
policies and the literature with double messages including mandatory and voluntary.  
 
Generally, consent is presumed for treatable disorders and explicit for additional testing for new 
disorders and for storage. (See TABLE 4) Defining what are treatable and non treatable 
conditions is important because some policies have waived the need for informed parental 
consent stating that mandatory programs do not require obtaining parental authorization, whether 
explicit (written or verbal) or implicit (informed refusal).45  
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Where explicit consent is not a requirement, such as in the case of screening for treatable 
disorders, it is suggested that presumed consent should not lead to uninformed parents nor should 
it create confusion in the health service community as to who is responsible for providing 
information prior to screening. Presumed consent to routine newborn screening does not obviate 
the possibility of parental refusal for a specific clinical diagnosis. However once the at-risk infant 
is identified, it is very difficult for parents to support the authority of presumed consent because 
current experience demonstrates that information about parental right to refuse screening, storage 
and future use of coded samples is seldom provided to parents when programs are “mandated” 
and where written consent is not a requirement.46 Nevertheless, from a child rights point of view, 
presumed consent to screening is defensible because it is every child’s right to be screened and 
found when treatments exist and are accessible.  
 
There is no doubt that public health authorities are required to provide the best possible health 
services to the public and specifically to newborns where early intervention can improve the 
outcome. However, NBS programmes are increasingly facing new challenges which raise 
questions about consent and how best to inform parents. Discussing the availability and the utility 
of tests for treatable or non-treatable conditions with parents might prove to be worthwhile.  
 
Providing prior written information gives parents the opportunity to learn about disorders 
included in the universal panel; additional disorders; disorders which are not included but for 
which tests do exist; storage and possible future use of stored DBS; and allows them to discuss 
any fears or apprehensions with their medical service provider beforehand. Some of the 
information may be best delivered by the obstetrician or mid-wife. With adequate training, these 
medical professionals will be best suited for the task as they are the ones who interact most with 
parents before and after birth. It is our opinion that obstetric and gynaecological societies should 
adopt guiding principles acknowledging the OB/GYN’s privileged position and relationship with 
expecting parents and the importance of their role in the newborn screening process. 
 
Indeed, as seen in the policy review, there are different ways in which information can be 
provided prior to newborn screening for treatable disorders, for new disorders, for storage and for 
the future use of stored samples. Overall there is a need for public and professional education and 
a better-informed public. Ideally, an informed choice model should be privileged, where 
information about screening and storage is conveyed to parents prior to the collection of the 
sample, well before the birth of the child and where presumed consent to screening is separate 
from explicit consent to screening for non-treatable disorders and from issues related to storage 
and future use of samples. This would allow the newborn to benefit from screening for treatable 
disorders even if parents refuse screening for conditions that are not treatable or for storage.  
 
 
In all policies regarding newborn screening and DBS storage, the interest of the newborn should 
be paramount. 
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Appendix 
 
 
Table 1. The Ten Principles of Neonatal Screening: Consensus statement from the 1989 workshop on 
“Genetic Screening: From Newborns to DNA typing” 
 
 
1. Newborn genetic screening is a medical act in the context of preventive medicine. 
 
2. Newborn genetic screening should lead to medical intervention for the benefit of the newborn. 
 
3. Newborn genetic screening should be universally and equitably available in the population(s) to be screened.
 
4. Newborn genetic screening programs should inform the parent(s) and the general public of their goals and 
objectives, of the disorders being screened for and the tests being performed. 
 
5. Newborn genetic screening programs should use testing procedures whose sensitivity, specificity and 
acceptability are known from pilot studies conducted in the population(s) to be tested. 
 
6. Newborn genetic screening programs should inform the parent(s) of the significance of the results of 
screening tests and should confirm that these results are validated by the standard diagnostic tests. 
 
7. Newborn genetic screening programs should integrate follow-up procedures into their system since it 
provides and validates the benefit to the newborn. Such follow-up should include referral to effective medical 
intervention and to other support services and resources. 
 
8. Newborn genetic screening programs could permit the use of their blood specimens for anonymous research 
or surveillance provided that the following conditions are met: 
i. Where the newborn screening programs are mandatory or operate as public health programs with 
an informed refusal approach: 
a. The public should be informed that such studies are being conducted. 
b. In surveillance for diseases where there is no effective intervention or benefit to the 
newborn, such surveillance should not only be anonymous but also unlinked as to avoid 
possible individual or population stigmatization or discrimination. 
c. The newborn genetic screening program itself should be responsible for assuring the 
unlinking of the nominative data and the complete anonymity of the sample of 
specimens used. 
d. Since surveillance studies benefit society, voluntary and free access to individual testing 
must be made available. 
ii. When the newborn genetic screening program requires fully informed individualized consent for 
screening, participation in anonymous research or surveillance studies requires a specific individual 
authorization. 
 
9. Newborn genetic screening programs should maintain the confidentiality of nominative information and 
samples unless proper authorization for release has been obtained. 
 
10. Newborn genetic screening programs could use DNA typing as a testing procedure when genetic 
heterogeneity in population(s) becomes technically interpretable. 
 
 
SOURCE: Bartha M. Knoppers & Claude M. Laberge, eds., Genetic Screening: from newborns to DNA typing, 
(Amsterdam: Excerpta Medica, 1990). 
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Table 2. What type of consent is required for newborn screening of treatable disorders? 
 
 
Explicit consent 
(written) 
 
Informed refusal 
 
Presumed Consent 
 
Informed choice 
 
 
• Scotland (pilot 
program) 
• AAP (2000) 
• Maryland, 
Wyoming, USA)  
 
 
• ISNS (2002) 
• HGSA (2004) 
• AWHONN (2004) 
• AFDPHE (1994) 
• APHL (2002) 
 
• Canada 
(no policies) 
• USA 
• UK 
 
• Proposed UK 
guidelines (2004) 
 
  
 
 
Table 3: Consent for DBS storage and future use beyond quality assurance 
 
                                              
1) When to inform about storage: 
Information should be provided to parents pre-natally. 
 
What to include:  
Include information about: purpose, length and method of storage, potential uses of residual samples, 
possibility or impossibility of being re-contacted, possibility or impossibility of receiving research results, 
ownership of samples, access to residual bloodspots, right to refuse storage or right of withdrawal at a later 
stage 
 
Type of consent to storage:                                    Written consent 
 
                                                                                          OR 
 
                                                                                                 Written refusal 
 
2) When to inform about future use: 
                                            
a) If at the time of collection, DBS are planned to be used in a research project 
 
 
                                                              
Written consent should be required at collection 
 
 
b) If at the time of collection no particular research use is foreseen 
            
                                    
 
Written consent OR Anonymization of samples WITH Ethical review board approval 
 
                                                                     is  required before samples are used 
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Table 4. Consent for newborn screening: treatable vs. untreatable 
 
 
1) When must information about newborn screening be provided to parents? 
Before the birth of a child 
 
2) What type of information should be provided?  
Information about treatable and untreatable disorders, opting out options, interpretation of test results, incidental 
findings, conditions that can be tested for but which are not included in the screening panel, etc. 
 
3) What type of consent is required? 
 
Screening for treatable disorders can require:       
               
o No consent (Presumed) 
o Written refusal 
o Written consent 
                                                                                                                                                                                       
Screening for untreatable disorders requires: 
 
o Written consent at all times 
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